We’re advancing a pipeline of pioneering therapies in oncology and inflammatory diseases, enabled by our groundbreaking scientific discoveries in glyco-immunology.

Oncology

Discovery
Lead-Op
IND-Enabling
Phase 1
Phase 2
E-602 Bi-Sialidase

E-602

Bi-Sialidase

Palleon’s lead program, E-602, is a first-in-class engineered human genetic fusion from Palleon’s EAGLE platform. The EAGLE (Enzyme-Antibody Glyco-Ligand Editing) platform enables creation of novel biological therapeutics by genetic fusion of human sialidase with human monoclonal antibodies. E-602 is designed to desialylate both immune cells and tumor cells.

E-602
IND-Enabling
Expected Q1 2022
TBD
PD-L1-Targeted Sialidase

PD-L1-Targeted Sialidase

PD-L1-Targeted Sialidase is a novel glyco-immunology therapeutic from Palleon’s EAGLE platform. The EAGLE (Enzyme-Antibody Glyco-Ligand Editing) platform enables creation of novel biological therapeutics by genetic fusion of human sialidase with human monoclonal antibodies. PD-L1-Targeted Sialidase is designed to target PD-L1-expressing tumors and immune cells to enhance the desialylation of both tumor cells and immune cells.

PD-L1-Targeted Sialidase
Lead-Op
HER2-Targeted Sialidase

HER2-Targeted Sialidase

HER2-Targeted Sialidase is a novel glyco-immunology therapeutic from Palleon’s EAGLE platform. The EAGLE (Enzyme-Antibody Glyco-Ligand Editing) platform enables creation of novel biological therapeutics by genetic fusion of human sialidase with human monoclonal antibodies. HER2-Targeted Sialidase is designed to target HER2-expressing tumors to enhance the desialylation of tumor cells. Both HER2-low and HER2-high expressing tumors can be treated with this therapy.

HER2-Targeted Sialidase
IND-Enabling

Inflammatory Diseases

Discovery
Lead-Op
IND-Enabling
Phase 1
Phase 2